Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe there are scheduling conflicts??
After all briefs and the joint appendix have been filed, the Clerk’s Office screens cases selected for oral argument to determine if they are calendar-ready.
B. Notice to Advise of Scheduling Conflicts
In counseled cases, the Clerk’s Office issues a Notice to Advise of Scheduling Conflicts after the close of merits briefing. Arguing counsel are asked to advise the Clerk’s Office within seven days of any conflicts for the next six court session months not already scheduled.
C. Response to Notice to Advise of Scheduling Conflicts
Within seven days after receiving notice from the Clerk’s Office, arguing counsel must identify conflicts with upcoming court dates through filing a Response to Notice to Advise of Scheduling Conflicts. Fed. Cir. R. 34(d)(2). A blank response form is available on the court’s website (Form 32). Counsel should review the Calendar of Sessions on the court’s website and identify only conflicts with scheduled court dates. Counsel should limit the number of scheduling conflicts during court weeks to assist with the timely scheduling of cases for argument.
One question - then why has Amarin even talked about coming out with their own GV if they lose? Not one public comment that they will just launch another round of patent protection attacks if they lose - why? Those comments (lack of) are what I can’t wrap my head around if they have another 50 orange book items to attack the generics with.
Remember - we are heavily owned by retail investors.....we are not the brightest at times
MEOWZA - is officially having too many drinks tonight?
Roger that....and thank you for your knowledge and leadership on the board...I will take my old fashion tonight and shut up and leave this board to the experts....thanks for the exchange ...best of luck to the longs and I have very awful thoughts for judge Du :-0
Please - I respect your posts and have learned a ton from you......so serious mad respect.......but let’s live in reality
Come on man - damages are in billions? Where the heck is that coming from? Don’t get delusional - it is what it is right now
Time it with Form 4’s hitting the wire for this quarter...#distraction
Because they already took it down....classic Amarin
JULY will be another dead month most likely
Where are the results? How long does it normally take to do post trial analysis?
NEW from Markman Advisors
Getting a reversal on appeal is hard. Yet, Amarin has undoubtedly made compelling arguments. While its odds of prevailing may still be less than likely, its briefing has raised those odds high enough to have a veritable fighting chance. The next big milestone will be the oral argument. Each side is technically permitted only fifteen-minutes of argument, but the Judges can extend that time if they wish to. During the oral argument, the Judges often ask questions, and those questions can sometimes be a tell into which issues the Court views to be most important.
https://www.markmanadvisors.com/blog/2020/6/29/amarin-what-does-amarins-reply-appellate-brief-say
So frustrating to see the patent moat surrounding the castle......but the generic cockroaches were able to build a bridge made of sticks to come on over and help themselves to whatever they want. “Off-Label” scripts will erode all our our protected IP.
Makes me so angry!!
I love the optimism for a possible settlement - but I don’t think it will happen.
I sure hope I’m wrong.
This is why Settlement will not happen now.
The Plaintiffs filed a patent infringement action against the defendant, Netskope, accusing Netskope of infringing U.S. Patent Number 7,305,707 (the “707 Patent”). Netskope filed a motion for judgment on the pleadings, which the district court granted finding that the asserted claims for the 707 Patent were unpatentable abstract ideas. The district court subsequently entered judgment in favor of Netskope, invalidating the ‘707 Patent.
After the Plaintiffs filed an appeal with the Federal Circuit, the parties settled the case and the Federal Circuit remanded the case back to the district court. The Plaintiffs then filed an unopposed motion to vacate the district court’s judgment invalidating the ‘707 Patent.
In support of their motion, the Plaintiffs argued that a vacatur of the judgment would be appropriate because, otherwise, they would be precluded from enforcing the 707 Patent against others and the judgment would not be subject to any appellate review. In addition, the Plaintiffs argued that the vacatur was an important factor in the settlement with Netskope and the beneficial effect of such settlement outweighs any public policy concerns.
The district court was not persuaded. “The Court finds that here, the balance of the equities weighs against vacating its judgment invalidating the 707 Patent. By their own admission, plaintiffs seek vacatur so that they may assert the 707 Patent again against others, which would result in unnecessary relitigation of issues already determined by this Court. ‘Judicial precedents are presumptively correct and valuable to the legal community as a whole. They are not merely the property of private litigants and should stand unless a court concludes that the public interest would be served by vacatur.’ U.S. Bancorp Mortg. v. Bonner Mall P’ship, 513 U.S. 18, 26-27 (1994) (citations omitted). That the judgment is unreviewed does not weigh in favor of vacatur here, where plaintiffs’ voluntary actions caused the mootness that prevented appellate review.”
The district court also rejected the Plaintiffs’ assertion that the beneficial effect of their settlement outweighed any other factors because the Plaintiffs admitted that the settlement was not contingent on the district court granting the motion for vacatur. See Reynolds v. Allstate Ins. Co., No. 10-CV-4893, 2012 WL 4753499, at *2 (N.D. Cal. Oct. 4, 2012) (denying vacatur where granting of vacatur was not necessary to consummation of settlement).
Accordingly, the district court denied the motion to vacate.
Market seems super impressed ....SMH
Writing style comparison between Singer and the generic attorneys - is night and day.
Singers approach is fluid and professional. Generics brief reads as if all the pages fell on floor and when put back together - topics are all out of sequence. Very weak and unpolished.
GAME.SET.MATCH
GENERICS FINISHED
MARKET HAS SPOKEN
People are not too excited for Singer brief dropping. I expected a small run up in anticipation of a masterpiece. But all we get is the normal dump.
But that trial (or article) is over a month old?
So why PR what is happening in Canada run by Canadian healthcare group
https://investor.amarincorp.com/news-releases/news-release-details/amarin-supports-trial-investigate-effects-vascepar-icosapent
BUT don’t PR a trial run by BHATT and sponsored by Amarin in Argentina?
90k on scripts tomm
I salute you sir!
What is revenue potential with our partnership in China? Anyone dare to estimate what the rev potential there might be?
This makes so much sense - that it ensures that is has zero chance of happening because, well, this is Amarin.
UM - said no one ever
Boehringer sells equity stake in Hikma.....due to them fundamentally disagreeing with the way they treated Amarin and how unethically they are being as it relates to trying to steal Amarins IP.
Additionally Hikma not settling with Amarin was the last straw for Boehringer.
I expect to see one from MRC. He’s been quiet on social media - which usually means he’s hard at work trying to unethically do something.
Read the thread from sts66 - it appears so
If this happens.....$25 min immediately
AMRN mark this post.....Prediction...Amarin announcements that it (as part of a settlement) will partner with Reddy and Hikma to market and distribute Vascepa in the Eu and Amarin will have United States and Canada 100% till 2029. JUST MY PREDICTION.
With the delay of marketing campaign - does that guarantee a positive cash flow quarter? Should we see a nice positive net quarter?
Reverse: 71.45%
Affirm: 18.55%
Remand: 7.25%
Settle: 2.75%
Rest In Peace......it’s over.....put a fork in it
ACST can finally RIP
The FDA confirmed that it will require pivotal efficacy analyses for TRILOGY 2 to be performed on the full Intent to Treat (ITT) population as contemplated in the original Statistical Analysis Plan (SAP), and they supported the conduct of post-hoc analyses in TRILOGY 1 for exploratory purposes. Consistent with the Company’s prior disclosures, and depending on the outcome of TRILOGY 2, an additional clinical study may still be needed prior to an NDA submission.
Is everyone over looking this?
“if they “win” appeal they still launch at risk...6 invalidated patents doesn’t stop Amarin for going after damages related to the other 50 OB’d patents.”
Why is no one talking about this?
Lets go red - why not
Procedural errors should trump all the other BS that the generics were spinning in their brief.
The errors alone should set Amarin up to win.
Okily Dokily
It’s going to be hard for these judges to read through these briefs and come to a conclusion....especially in our favor since the burden is on Amrn.
I thought the generics brief was well written. Both sides had well written briefs.
This makes me sick to my stomach - the thought of it being upheld.
I think AMRN really needs some luck now. Is that Luck - Singer ....I hope so.
Vacated how? The generics would have to raise their hand and say that DU made mistakes and we want to do the right thing by suggesting that the ruling be reversed?
No chance
The patents were already made invalid....why/how would a settlement by Reddy make sense now.....
PATENTS HAVE BEEN INVALIDATED
Appeal must be finished